- Featured on SmallCapVoice.com interview, Warren Wang outlines plans for CIIX subsidiary, CBD Biotech Inc.
- CBD Biotech one of few players in China’s fast-growing CBD market
- Company to focus on hemp/CBD-infused cosmetic products
ChineseInvestors.com Inc. (OTCQB: CIIX) provides prominent financial information for Chinese-speaking investors in both China as well as the United States. The company is also a leading hemp retailer looking to capitalize on the growing market for hemp/CBD products in China.
During a recent SmallCapVoice.com interview, CIIX CEO Warren Wang provided updates about CIIX as well as its subsidiary, CBD Biotech (http://ibn.fm/1azD1). In the interview, Wang explains the enormous market opportunity in China for CBD/hemp-infused cosmetic products, such as lotion and anti-aging cream.
While the sale of hemp and CBD oil in cosmetics is permitted, China has not yet approved these products for use in food or medicine; however, given worldwide legalization trends, this is likely to change in the near future. CBD Biotech is an early player in China’s CBD sector, and Wang is optimistic about the company’s future in the promising market. “CBD-infused or hemp-infused cosmetic products [are] still very early stage in China,” he said. “We are only one of few players in the market, and I think 2020 will give us a lot of opportunities.”
The CIIX CEO views the growth of CBD Biotech as one of the major milestones for CIIX in 2019. In mid-November of this year, CIIX’s subsidiary was featured in a Wall Street Journal report about the growing cannabis industry in China. CEO of CBD Biotech SEO Summer Yun said (http://ibn.fm/1XUcw) that “[a]s one of the first movers in the legal industrial hemp skincare and cosmetics market, we are honored to be featured in this recent Wall Street Journal report and believe that this mention validates our efforts in China over the past few years.”
CIIX began in 1999. Two decades later, the company has a promising subsidiary that is poised to become a major player in China’s cannabis industry. While marijuana and THC are still illegal in China, Chinese entrepreneurs are looking to cash in on China’s inevitable CBD boom.
When asked about his goals for 2020, CIIX’s ambitious CEO had a lot to say. Wang noted that plans are in place to consolidate the China and U.S. divisions, with headquarters in China. According to Wang, CBD Biotech has already had more than 40,000 repeat purchase customers, and he believes that the company will continue accumulating customers in 2020 through both B2B and direct sales (http://ibn.fm/StJT1).
“China is a market that you cannot ignore in the next 10 to 20 years in the cannabis sectors,” said Wang, who expressed confidence that CBD Biotech can accumulate millions of regular Chinese customers within the next decade.
ChineseInvestors.com continues to help investors make informed investment decisions and meet their individual financial goals. The company is also at the vanguard of capitalizing on the convergence of CBD and the nutrition- and health-products market in mainland China. ChineseInvestors.com offers investors diverse revenue streams for potential portfolio growth.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.